ES2535723T3 - Métodos de determinación de la respuesta del paciente mediante la medición de Her-3 - Google Patents

Métodos de determinación de la respuesta del paciente mediante la medición de Her-3 Download PDF

Info

Publication number
ES2535723T3
ES2535723T3 ES10732183.8T ES10732183T ES2535723T3 ES 2535723 T3 ES2535723 T3 ES 2535723T3 ES 10732183 T ES10732183 T ES 10732183T ES 2535723 T3 ES2535723 T3 ES 2535723T3
Authority
ES
Spain
Prior art keywords
sample
preferable embodiment
cancer
antibody
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10732183.8T
Other languages
English (en)
Spanish (es)
Inventor
Michael Bates
Jennifer W. Cook
Gundo Diedrich
Laurie Goodman
Ali Mukherjee
Gordon Parry
Jeff Sperinde
Stephen John Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Labcorp Holdings Inc
Original Assignee
Laboratory Corp of America Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratory Corp of America Holdings filed Critical Laboratory Corp of America Holdings
Application granted granted Critical
Publication of ES2535723T3 publication Critical patent/ES2535723T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES10732183.8T 2009-01-15 2010-01-15 Métodos de determinación de la respuesta del paciente mediante la medición de Her-3 Active ES2535723T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US176630P 2000-01-19
US14502909P 2009-01-15 2009-01-15
US145029P 2009-01-15
US17663009P 2009-05-08 2009-05-08
US18796209P 2009-06-17 2009-06-17
US187962P 2009-06-17
PCT/US2010/021281 WO2010083470A1 (en) 2009-01-15 2010-01-15 Methods of determining patient response by measurement of her-3

Publications (1)

Publication Number Publication Date
ES2535723T3 true ES2535723T3 (es) 2015-05-14

Family

ID=42340114

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10732183.8T Active ES2535723T3 (es) 2009-01-15 2010-01-15 Métodos de determinación de la respuesta del paciente mediante la medición de Her-3

Country Status (12)

Country Link
US (4) US8349574B2 (enExample)
EP (1) EP2387711B1 (enExample)
JP (1) JP5746051B2 (enExample)
KR (1) KR20110120891A (enExample)
CN (1) CN102460152B (enExample)
AU (1) AU2010204583A1 (enExample)
BR (1) BRPI1007321A2 (enExample)
CA (1) CA2749846C (enExample)
ES (1) ES2535723T3 (enExample)
IL (1) IL214072A (enExample)
SG (2) SG172983A1 (enExample)
WO (1) WO2010083470A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
AU2008230795B2 (en) 2007-03-27 2014-05-29 Bioassets, Llc Constructs and libraries comprising antibody surrogate light chain sequences
WO2009070772A1 (en) 2007-11-27 2009-06-04 Monogram Biosciences, Inc. Enhanced method for detecting and/or quantifying an analyte in a sample
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
US11401344B2 (en) 2008-12-01 2022-08-02 Laboratory Corporation Of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
US20120295259A1 (en) * 2011-05-19 2012-11-22 Laboratory Corporation Of America Holdings Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
EP2438442B1 (en) 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
US20100233732A1 (en) * 2009-01-15 2010-09-16 Laboratory Corporation Of America Holdings Methods of Determining Patient Response By Measurement of HER-2 Expression
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
NZ596468A (en) * 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
US9714937B2 (en) 2009-10-13 2017-07-25 Nanostring Technologies, Inc. Protein detection via nanoreporters
PH12012501157A1 (en) 2009-12-22 2012-10-29 Roche Glycart Ag Anti-her3 antibodies and uses thereof
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
EP2707723B1 (en) * 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
CA2842860A1 (en) * 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
AU2014244618A1 (en) 2013-03-13 2015-10-08 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
CA2908515A1 (en) * 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
CA2924386C (en) * 2013-10-04 2021-07-20 F. Hoffmann-La Roche Ag Antibodies specifically binding to her3
DK3805268T3 (da) 2014-02-28 2025-01-20 Merus Nv Antistof, der binder erbb-2 og erbb-3
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
US10501777B2 (en) 2015-07-17 2019-12-10 Nanostring Technologies, Inc. Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue
CN114350752B (zh) 2015-07-17 2025-02-25 布鲁克空间生物学公司 在横切面组织的用户定义区域中的基因表达的同时定量
JP7296728B2 (ja) 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
US10451614B2 (en) 2016-03-15 2019-10-22 Laboratory Corporation Of America Holdings Methods of assessing protein interactions between cells
MX2019011658A (es) 2017-03-31 2019-11-18 Merus Nv Agente que se dirige al receptor 2 del factor de crecimiento epidermico humano (erbb-2) y anticuerpo biespecifico con sitios de union a antigeno que se unen a un epitopo sobre una parte extracelular de erbb-2 y el receptor 3 del factor de crecimiento epidermico humano (erbb-3), para el tratamiento de un individuo con un tumor positivo para erbb-2, erbb-2/erbb-3.
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
EP3625264B9 (en) 2017-05-17 2023-10-25 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
RS66708B9 (sr) 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
JP7372927B6 (ja) 2018-02-12 2023-11-27 ナノストリング テクノロジーズ，インコーポレイティド 遺伝子およびタンパク質の発現を検出する生体分子プローブおよびその検出方法

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5117165B1 (enExample) 1973-12-27 1976-05-31
US4318846A (en) 1979-09-07 1982-03-09 Syva Company Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
JP2681061B2 (ja) 1988-06-08 1997-11-19 ロンドン・ダイアグノスティック・インコーポレーテッド 検出可能なシグナルのセンシタイザー誘導発生を利用したアッセイ
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
ATE146508T1 (de) 1990-11-02 1997-01-15 Zeneca Ltd Polysubstituierte phthalocyanine
US5340716A (en) 1991-06-20 1994-08-23 Snytex (U.S.A.) Inc. Assay method utilizing photoactivated chemiluminescent label
US5578498A (en) 1991-05-22 1996-11-26 Behringwerke Ag Metal chelate containing compositions for use in chemiluminescent assays
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
JP3464798B2 (ja) 1992-07-31 2003-11-10 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 光活性化化学発光基質
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
AU707440B2 (en) 1994-03-29 1999-07-08 Celltech Therapeutics Limited Antibodies against E-selectin
US5986076A (en) 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
SE9601676D0 (sv) 1996-04-30 1996-04-30 Ulf Landegren Improved probing of specific mucleic acids
US5945526A (en) 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US6001673A (en) 1999-02-11 1999-12-14 Ericsson Inc. Methods for packaging integrated circuit devices including cavities adjacent active regions
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6514700B1 (en) 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6682887B1 (en) 1999-04-30 2004-01-27 Aclara Biosciences, Inc. Detection using degradation of a tagged sequence
US20040248150A1 (en) 1999-04-02 2004-12-09 Sharat Singh Methods employing oligonucleotide-binding e-tag probes
US20030092012A1 (en) 2001-11-09 2003-05-15 Ahmed Chenna Methods for detecting a plurality of analytes by chromatography
US7037654B2 (en) 1999-04-30 2006-05-02 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
US6673550B2 (en) 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US7001725B2 (en) 1999-04-30 2006-02-21 Aclara Biosciences, Inc. Kits employing generalized target-binding e-tag probes
US6649351B2 (en) 1999-04-30 2003-11-18 Aclara Biosciences, Inc. Methods for detecting a plurality of analytes by mass spectrometry
US20030235832A1 (en) 2000-06-21 2003-12-25 Ahmed Chenna Multiplexed analysis by chromatographic separation of molecular tags
SI1187632T1 (sl) 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
EP2110138A1 (en) 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
CA2397417A1 (en) * 2000-01-12 2001-07-19 Sarah S. Bacus Method for quantitating a protein by image analysis
US7306904B2 (en) 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing
MY133839A (en) 2000-03-14 2007-11-30 Shell Int Research Process for the carbonylation of pentenenitrile
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
US7537938B2 (en) 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US20030207300A1 (en) 2000-04-28 2003-11-06 Matray Tracy J. Multiplex analytical platform using molecular tags
US20040067498A1 (en) 2000-04-28 2004-04-08 Ahmed Chenna Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
US7771929B2 (en) 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
US7160735B2 (en) 2000-04-28 2007-01-09 Monogram Biosciences, Inc. Tagged microparticle compositions and methods
US20030170734A1 (en) 2000-04-28 2003-09-11 Stephen Williams Multiplexed assays using electrophoretically separated molecular tags
EP1305632B1 (en) 2000-05-04 2011-07-27 Siemens Healthcare Diagnostics Products GmbH Methods for detection of multiple analytes
US6547654B2 (en) 2000-07-22 2003-04-15 Americo Del Raso Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander
AU7922201A (en) 2000-08-08 2002-02-18 Aclara Biosciences Inc Multiplexed enzymatic assays
AU2001280222A1 (en) 2000-08-19 2002-03-04 Sung-Cheol Kim Communication line separator
EP1236740B1 (de) 2001-02-28 2012-07-18 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
CZ20033143A3 (en) 2001-05-21 2004-04-14 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
US7041459B2 (en) 2001-05-21 2006-05-09 Monogram Biosciences, Inc. Analyzing phosphorylated proteins
AU2002344221A1 (en) 2001-05-26 2002-12-09 Aclara Biosciences, Inc. Catalytic amplification of multiplexed assay signals
AU2002316577A1 (en) 2001-07-09 2003-01-29 Aclara Biosciences, Inc. Cell-screening assay and composition
US7446185B2 (en) 2001-07-18 2008-11-04 The Regents Of The University Of California Her2/neu target antigen and use of same to stimulate an immune response
US20040241688A1 (en) 2001-07-19 2004-12-02 Cuneyt Bukusoglu Human tissue specific drug screening procedure
GB2378245A (en) 2001-08-03 2003-02-05 Mats Nilsson Nucleic acid amplification method
EP1414496B1 (en) 2001-08-07 2010-10-20 Galephar M/F Pharmaceutical composition containing a combinaition of ppar-alpha, pravastatin and polyglycolized glyceride
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
US20050043820A1 (en) 2001-10-12 2005-02-24 James Browning Biomaterial comprising microfeatures
WO2003033741A1 (en) 2001-10-16 2003-04-24 Aclara Biosciences, Inc. Universal e-tag primer and probe compositions and methods
US7045311B2 (en) 2001-10-25 2006-05-16 Monogram Biosciences, Inc. Whole cell assay systems for cell surface proteases
EP1456657A4 (en) 2001-11-09 2008-03-12 Aclara Biosciences Inc MARKER MICROPARTICLE COMPOSITIONS AND RELATED METHODS
JP2005511033A (ja) 2001-11-09 2005-04-28 アクララ バイオサイエンシーズ， インコーポレイテッド タグ含有構築物の切断および分離による核酸配列の決定
WO2003042658A2 (en) 2001-11-09 2003-05-22 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
WO2003051669A1 (en) 2001-12-18 2003-06-26 Aclara Biosciences, Inc. Photoactivation device and method
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
CN1317303C (zh) * 2002-02-26 2007-05-23 希格马托制药工业公司 抗人腱生蛋白单克隆抗体
EP1478765A4 (en) 2002-03-05 2006-12-06 Aclara Biosciences Inc MULTIPLEX ANALYSIS USING MEMBRANE-FIXED SENSITIZERS
US7081340B2 (en) 2002-03-13 2006-07-25 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
EP1490533A4 (en) 2002-04-02 2007-07-04 Aclara Biosciences Inc MULTIPLEXASSAYS USING ELECTROPHORETICALLY SEPARATED MOLECULAR MARKERS
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229299A1 (en) 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040229293A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20090111127A1 (en) 2002-05-21 2009-04-30 Monogram Biosciences Inc. Surface Receptor Complexes as Biomarkers
US20040175765A1 (en) 2002-07-05 2004-09-09 Sharat Singh Cell-screening assay and composition
HUP0600340A3 (en) * 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
ATE442589T1 (de) 2002-07-25 2009-09-15 Aclara Biosciences Inc Nachweis der rezeptoroligomerisierung
CA2493671A1 (en) 2002-07-26 2004-02-05 Aclara Biosciences, Inc. Lipophilic electrophoretic probes
US20040091850A1 (en) 2002-11-08 2004-05-13 Travis Boone Single cell analysis of membrane molecules
AU2003291249A1 (en) 2002-12-18 2004-07-29 Aclara Biosciences, Inc. Multiplexed immunohistochemical assays using molecular tags
EP1599492A4 (en) 2003-01-17 2008-09-24 Virologic Inc RECIPIENTS DORPHANIZATION BY USING MARKED MOLECULAR LIBRARIES
BRPI0408928A (pt) 2003-04-01 2006-09-12 Monogram Biosciences Inc métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
US20100291594A1 (en) 2003-07-17 2010-11-18 Laboratory Corporation Of America Holdings ErbB Surface Receptor Complexes as Biomarkers
WO2005011607A2 (en) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
EP1673399B1 (en) 2003-08-11 2017-04-05 Monogram BioSciences, Inc. Detecting and profiling molecular complexes
EP1664716A4 (en) 2003-08-15 2008-08-13 Smithkline Beecham Corp CANCER BIOMARKERS
US20050106571A1 (en) 2003-10-02 2005-05-19 The Regents Of The University Of California Mammalian T1R3 sweet taste receptors
WO2005037071A2 (en) 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
CA2543830A1 (en) 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detecting human anti-therapeutic antibodies
AU2005256113B2 (en) * 2004-07-09 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
WO2006044748A2 (en) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
CN101137758B (zh) 2004-11-03 2012-10-10 意力速分子诊断股份有限公司 均相分析物检测
US7939267B2 (en) 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
US7862995B2 (en) * 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
WO2006068640A1 (en) * 2004-12-21 2006-06-29 Cell Signaling Technology, Inc. Protein phosphorylation in egfr-signaling pathways
WO2006084018A2 (en) 2005-02-02 2006-08-10 Monogram Biosciences, Inc. Methods for determining responsiveness to cancer therapy
WO2006086730A2 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting her2 shedding with matrix metalloprotease antagonists
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
WO2006133460A2 (en) * 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
CN1928563B (zh) 2005-09-09 2010-04-28 上海张江生物技术有限公司 乳腺癌的免疫组化诊断试剂盒和测试片
WO2007041502A2 (en) * 2005-09-30 2007-04-12 Monogram Biosciences Methods for determining responsiveness to cancer therapy
EP2049568A2 (en) 2006-04-07 2009-04-22 Københavns Universitet Erbb receptor-derived peptide fragments
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
JP5117165B2 (ja) 2007-11-09 2013-01-09 花王株式会社 水中油型乳化組成物の製造方法
WO2009070772A1 (en) 2007-11-27 2009-06-04 Monogram Biosciences, Inc. Enhanced method for detecting and/or quantifying an analyte in a sample
CN101230390A (zh) 2007-12-07 2008-07-30 湖北大学 一种用于妇科恶性肿瘤早期筛选的基因芯片及其检测方法
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
ES2342646B1 (es) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
EP2438442B1 (en) 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
US20100233732A1 (en) 2009-01-15 2010-09-16 Laboratory Corporation Of America Holdings Methods of Determining Patient Response By Measurement of HER-2 Expression
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.

Also Published As

Publication number Publication date
EP2387711A4 (en) 2012-07-18
CN102460152A (zh) 2012-05-16
US8349574B2 (en) 2013-01-08
SG10201408392PA (en) 2015-01-29
US20160061839A1 (en) 2016-03-03
US9110066B2 (en) 2015-08-18
AU2010204583A1 (en) 2011-08-25
JP5746051B2 (ja) 2015-07-08
IL214072A (en) 2016-08-31
EP2387711A1 (en) 2011-11-23
BRPI1007321A2 (en) 2018-07-10
AU2010204583A2 (en) 2011-09-01
CA2749846C (en) 2018-08-07
US20130071859A1 (en) 2013-03-21
IL214072A0 (en) 2011-08-31
WO2010083470A1 (en) 2010-07-22
CA2749846A1 (en) 2010-07-22
US9766242B2 (en) 2017-09-19
US10775382B2 (en) 2020-09-15
SG172983A1 (en) 2011-08-29
EP2387711B1 (en) 2015-04-22
CN102460152B (zh) 2014-11-26
US20180164319A1 (en) 2018-06-14
KR20110120891A (ko) 2011-11-04
US20100210034A1 (en) 2010-08-19
JP2012515226A (ja) 2012-07-05

Similar Documents

Publication Publication Date Title
US10775382B2 (en) Methods of determining patient response by measurement of HER-3
US10273308B2 (en) Methods of producing antibodies specific for p95
ES2526519T3 (es) Métodos de determinación de la respuesta del paciente por medición de la expresión HER-2
US20090191559A1 (en) Her2 diagnostic methods
US20130216523A1 (en) Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression
ES2701929T3 (es) Métodos para determinar la probabilidad de supervivencia y para predecir la probabilidad de metástasis en el cáncer
ES2827215T3 (es) Métodos para detectar moléculas en una muestra
ES2285469T3 (es) Utilizacion de la proteina celular transportadora de acido retinoico de tipo ii (crabp ii) como marcador del cancer de mama.
Wang et al. Expression Characteristics of Clinically Relevant Antibody–Drug Conjugate Targets in Gestational Trophoblastic Neoplasia
US20080299589A1 (en) Methods and Materials for Examining the P13k/Akt Pathway in Gliomas and Prostate Cancers